删除RalGAPβ可以保护胰腺β细胞,并改善血糖控制
Weikuan Feng1,2, Sangsang Zhu1,2, Lingchen Kong1,2
1State Key Laboratory of Pharmaceutical Biotechnology, Department of Endocrinology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Model Animal Research Center, Nanjing University, Nanjing, China.
Diabetes, obesity & metabolism
|September 16, 2025
概括
拉尔GAP复合体调节胰腺β细胞功能. 删除RalGAPβ可以增强β细胞的增殖和胰岛素的分泌,改善葡萄糖耐受性,并为2型糖尿病治疗提供潜在的可能性.
科学领域:
- 内分泌学 在内分泌学.
- 细胞生物学 细胞生物学
- 代谢研究研究 代谢研究
背景情况:
- 胰腺β细胞平衡对于血糖控制至关重要.
- 调节β细胞功能和胰岛素分泌的机制需要进一步阐明.
研究的目的:
- 研究Ral-GTPase激活蛋白 (RalGAP) 复合体在β细胞稳态和胰岛素分泌中的作用.
主要方法:
- 使用胰腺β细胞特异的RalGAPβ淘汰小鼠和RalGAPβ淘汰INS-1细胞.
- 进行了代谢表型,免疫阻塞,RT-QPCR,葡萄糖刺激胰岛素分泌 (GSIS) 试验,增殖和亡试验,RNA测序和代谢分析.
主要成果:
- 高脂肪饮食降低了小岛上的活性RalA;RalGAPβ删除提高了活性RalA,促进了β细胞的增殖和大小.
- 拉尔GAPβ缺乏抑制了亡,增强了胰岛素分泌 (KCl刺激和GSIS),并改善了葡萄糖耐受性.
- 在分子层面上,RalGAPβ删除调节了GLUT1/GLUT2表达,并激活了p70S6-激酶,推动了增殖.
结论:
- 拉尔GAP复合体是β细胞平衡和胰岛素分泌的关键调节者.
- 准RalGAP复合体可能提供一种治疗策略,用于保护2型糖尿病中的β细胞.
相关概念视频
Glucagon-like Receptor Agonists
850
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
850
Dipeptidyl Peptidase 4 Inhibitors
596
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
596
Hormones Regulating Blood Glucose
6.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.5K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
526
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
526


